SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ZLAB alert in real time by email
SC 13G/A 1 dp188767_sc13ga-4.htm FORM SC 13G/A

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G/A

 

(Amendment No. 4)*

 

Under the Securities Exchange Act of 1934

 

Zai Lab Limited

(Name of Issuer)

 

Ordinary shares, par value US$0.000006 per share

(Title of Class of Securities)

 

98887Q104**

(CUSIP Number)

 

December 31, 2022

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  Rule 13d-1(b)

 

  Rule 13d-1(c)

 

  Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

**There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 98887Q104 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Stock Exchange under the symbol “ZLAB.” Each ADS represents 10 Ordinary Shares.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 98887Q104

 

1. 

NAMES OF REPORTING PERSON

 

Qiming Corporate GP IV, Ltd.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

 

(a)       

(b)       

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

SOLE VOTING POWER

 

79,229,320(1)

6.

SHARED VOTING POWER

 

None

7. 

SOLE DISPOSITIVE POWER

 

79,229,320(1)

8. 

SHARED DISPOSITIVE POWER

 

None

9. 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

79,229,320(1)

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

 

(see instructions)

11. 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

8.1%(2)

12.

TYPE OF REPORTING PERSON (see instructions)

 

CO

 

(1) As of the date of this 13G/A filing, Qiming Corporate GP IV, Ltd. is the general partner of Qiming Managing Directors Fund IV, L.P. and Qiming GP IV, L.P. Qiming Managing Directors Fund IV, L.P. holds approximately 3.06% of the equity interest of QM11 Limited. Qiming GP IV, L.P. is the general partner of Qiming Venture Partners IV, L.P., which holds approximately 96.94% of the equity interest of QM11 Limited. QM11 Limited is the owner of 79,229,320 Ordinary Shares (in the form of ADSs and 66,549,320 Ordinary Shares).

 

(2) The percentage is calculated based upon an aggregate of 979,087,430 Ordinary Shares outstanding as of December 31, 2022, which is based on the information disclosed by the Issuer on January 6, 2023.

 

2 

 

CUSIP No. 98887Q104

 

1.

NAMES OF REPORTING PERSON

 

Qiming Managing Directors Fund IV, L.P. 

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

 

(a)

(b)

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

SOLE VOTING POWER

 

None

6.

SHARED VOTING POWER

 

2,425,051(3) 

7.

SOLE DISPOSITIVE POWER

 

None

8.

SHARED DISPOSITIVE POWER

 

2,425,051(3) 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

‎2,425,051(3) 

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

 

(see instructions)

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

‎0.3%(4)‎

12.

TYPE OF REPORTING PERSON (see instructions)

 

PN

 

(3) As of the date of this 13G/A filing, Qiming Managing Directors Fund IV, L.P. holds approximately 3.06% of the equity interest of QM11 Limited, which is the owner of 79,229,320 Ordinary Shares (in the form of ADSs and 66,549,320 Ordinary Shares).

 

(4) The percentage is calculated based upon an aggregate of 979,087,430 Ordinary Shares outstanding as of December 31, 2022, which is based on the information disclosed by the Issuer on January 6, 2023. 

 

3 

 

CUSIP No. 98887Q104

 

1.

NAMES OF REPORTING PERSON

 

Qiming GP IV, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

 

(a)

(b)

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

SOLE VOTING POWER

 

None

6.

SHARED VOTING POWER

 

76,804,269(5)

7.

SOLE DISPOSITIVE POWER

 

None

8.

SHARED DISPOSITIVE POWER

 

‎76,804,269(5)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

76,804,269(5)

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

 

(see instructions)

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.8%(6)‎

12.

TYPE OF REPORTING PERSON (see instructions)

 

PN

 

(5) As of the date of this 13G/A filing, Qiming GP IV, L.P. is the general partner of Qiming Venture Partners IV, L.P., which owns approximately 96.94% of the equity interest of QM11 Limited, which is the owner of 79,229,320 Ordinary Shares (in the form of ADSs and 66,549,320 Ordinary Shares).

 

(6) The percentage is calculated based upon an aggregate of 979,087,430 Ordinary Shares outstanding as of December 31, 2022, which is based on the information disclosed by the Issuer on January 6, 2023. 

 

4 

 

CUSIP No. 98887Q104

 

1.

NAMES OF REPORTING PERSON

 

Qiming Venture Partners IV, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

 

(a)

(b)

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

SOLE VOTING POWER

 

None

6.

SHARED VOTING POWER

 

76,804,269(7)

7.

SOLE DISPOSITIVE POWER

 

None

8.

SHARED DISPOSITIVE POWER

 

76,804,269(7)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

76,804,269(7)

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

 

(see instructions)

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.8%(8)‎

12.

TYPE OF REPORTING PERSON (see instructions)

 

PN

 

(7) As of the date of this 13G/A filing, Qiming Venture Partners IV, L.P. holds approximately 96.94% of the equity interest of QM11 Limited, which is the owner of 79,229,320 Ordinary Shares (in the form of ADSs and 66,549,320 Ordinary Shares).

 

(8) The percentage is calculated based upon an aggregate of 979,087,430 Ordinary Shares outstanding as of December 31, 2022, which is based on the information disclosed by the Issuer on January 6, 2023.

 

5 

 

CUSIP No. 98887Q104

 

1.

NAMES OF REPORTING PERSON

 

QM11 Limited

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

 

(a)

(b)

3.SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Hong Kong

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

SOLE VOTING POWER

 

79,229,320

6.

SHARED VOTING POWER

 

None

7.

SOLE DISPOSITIVE POWER

 

79,229,320

8.

SHARED DISPOSITIVE POWER

 

None

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

79,229,320

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

 

(see instructions)

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

8.1%(9) 

12.

TYPE OF REPORTING PERSON (see instructions)

 

CO

 
(9) The percentage is calculated based upon an aggregate of 979,087,430 Ordinary Shares outstanding as of December 31, 2022, which is based on the information disclosed by the Issuer on January 6, 2023.

6 

 

Item 1.

 

  (a) Name of Issuer

 

Zai Lab Limited (the “Issuer”)

 

  (b) Address of Issuer’s Principal Executive Offices

 

The Issuer’s principal executive offices are located at 4560 Jinke Road, Bldg.1, 4F, Pudong, Shanghai, China 201210 and 314 Main Street 4th Floor, Suite 100 Cambridge, MA, USA 02142.

 

Item 2.

 

  (a) Name of Person Filing

 

Qiming Corporate GP IV, Ltd.

Qiming Managing Directors Fund IV, L.P.

Qiming GP IV, L.P.

Qiming Venture Partners IV, L.P.

QM11 Limited

 

  (b) Address of the Principal Office or, if None, Residence

 

The registered address of each of Qiming Corporate GP IV, Ltd., Qiming Managing Directors Fund IV, L.P., Qiming GP IV, L.P. and Qiming Venture Partners IV, L.P. is M&C Corporate Services Limited, P.O. Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

 

The registered address of QM11 Limited is Units 4205-06, 42nd Floor, Gloucester Tower, the Landmark, 15 Queen’s Road Central, Hong Kong.

 

  (c) Citizenship

 

Qiming Corporate GP IV, Ltd., Qiming Managing Directors Fund IV, L.P., Qiming GP IV, L.P. and Qiming Venture Partners IV, L.P. are organized in Cayman Islands.

 

QM11 Limited is a company organized in Hong Kong.

 

  (d) Title of Class of Securities

 

Ordinary Shares, par value of $0.000006 per share (the "Ordinary Shares").

 

  (e) CUSIP Number

 

There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 98887Q104 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Stock Exchange under the symbol “ZLAB.” Each ADS represents 10 Ordinary Shares.

 

Item 3. Statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c):

 

Not applicable.

 

Item 4. Ownership.

 

7 

 

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person and is incorporated herein by reference.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certification.

 

Not applicable.

 

8 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2023

 

  Qiming Corporate GP IV, Ltd.
   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

 

Qiming Managing Directors Fund IV, L.P.

By: Qiming Corporate GP IV, Ltd.,

its General Partner

   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

 

Qiming GP IV, L.P.

By: Qiming Corporate GP IV, Ltd.,

its General Partner

   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

 

Qiming Venture Partners IV, L.P.

By: Qiming GP IV, L.P.,

its General Partner

By: Qiming Corporate GP IV, Ltd.,

General Partner of Qiming GP IV., L.P.

   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

  QM11 Limited
   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Director

9 

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees that (i) this statement on Schedule 13G has been adopted and filed on behalf of each of them and (ii) all future amendments to such statement on Schedule 13G will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G as to any of the undersigned upon such person giving written notice thereof to each of the other persons signatory hereto, at the principal office thereof.

 

Dated: February 13, 2019

 

  Qiming Corporate GP IV, Ltd.
   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

 

Qiming Managing Directors Fund IV, L.P.

By: Qiming Corporate GP IV, Ltd.,

its General Partner

   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

 

Qiming GP IV, L.P.

By: Qiming Corporate GP IV, Ltd.,

its General Partner

   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

 

Qiming Venture Partners IV, L.P.

By: Qiming GP IV, L.P.,

its General Partner

By: Qiming Corporate GP IV, Ltd.,

General Partner of Qiming GP IV., L.P.

   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Authorized Signatory

 

 

  QM11 Limited
   
   
  By: /s/ Grace Lee
    Name: Grace Lee
    Title: Director

10 

Get the next $ZLAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZLAB

DatePrice TargetRatingAnalyst
3/7/2025$55.00Sector Outperform
Scotiabank
3/3/2025$29.00 → $36.10Buy → Neutral
BofA Securities
12/14/2023$47.50Overweight
Morgan Stanley
8/10/2023$70.00Overweight
Cantor Fitzgerald
3/2/2022$194.00 → $102.00Outperform
SVB Leerink
1/21/2022$64.00Outperform
Macquarie
12/15/2021$189.00 → $136.00Overweight
JP Morgan
11/11/2021$222.00 → $217.00Buy
Citigroup
More analyst ratings

$ZLAB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

    Poster presentation will highlight the potential of ZL-6201 as an innovative antibody-drug conjugate (ADC) for the treatment of sarcoma and other leucine-rich repeat-containing protein 15 (LRRC15)-positive solid tumors Late-breaking poster presentation will summarize data from preclinical evaluation of ZL-1222, a promising next-generation interleukin-12 (IL-12) immunocytokine therapy for the treatment of various cancers Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that data from preclinical studies of the Company's internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

    Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. "In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "Treatment options for patients experiencing recurrence or metastasis after initial treatment are limited. TIVDAK, the only antibody-drug conjugate (ADC)

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Zai Lab Announces Participation in Investor Conferences in March 2025

    Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in March 2025: Leerink Partners 2025 Global Healthcare Conference Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST Location: Miami, FL Jefferies Biotech on the Beach Summit Time: Tuesday, March 11, 2025 Location: Miami, FL A live webcast of the fireside chat will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-presentations and archived replay will be available for up to 90 days following the completion of the event. About Zai Lab Zai Lab (NASDAQ:ZLAB, HKEX: 9688)

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ZLAB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ZLAB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ZLAB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ZLAB
SEC Filings

See more

$ZLAB
Leadership Updates

Live Leadership Updates

See more
  • Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

      Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Zai Lab Appoints Michel Vounatsos To Its Board of Directors

    SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

    SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ZLAB
Financials

Live finance-specific insights

See more
  • Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

    - Company to host conference call and webcast on February 27, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration Link: https

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

    Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT in schizophrenia; expected regulatory submission in early 2025 Global Phase 1 data of ZL-1310 (DLL3 ADC) suggests best-in-class potential in extensive-stage SCLC Three product launches in mainland China expected by the end of 2024, and up to four potential regulatory submissions to the NMPA in the next six months Strong balance sheet with a cash position1 of $716.1 million as of September 30, 2024, compared to $730.0 million as of June 30, 2024 Conference call and webcast today, November 12, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab L

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

    -- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK) and safety profile support continued evaluation of ZL-1310 as a single agent and in combination for the treatment of extensive-stage SCLC in recurrent and first-line therapy -- Zai Lab to host conference call and webcast to discuss data on October 24, 2024, at 8:30 a.m. ET, following presentation of the data at ENA Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC)

    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ZLAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more